Transenterix Inc (TRXC) Coverage Initiated by Analysts at B. Riley
B. Riley started coverage on shares of Transenterix Inc (NYSEMKT:TRXC) in a research report report published on Friday morning. The brokerage issued a buy rating and a $3.00 target price on the stock.
Transenterix (NYSEMKT:TRXC) traded up 1.63% during mid-day trading on Friday, reaching $1.87. 471,944 shares of the company’s stock were exchanged. The firm’s market cap is $215.05 million. The stock has a 50-day moving average of $1.52 and a 200-day moving average of $2.03. Transenterix has a 12 month low of $1.03 and a 12 month high of $6.10.
Hedge funds and other institutional investors have recently made changes to their positions in the company. State Street Corp increased its position in shares of Transenterix by 65.7% in the first quarter. State Street Corp now owns 684,234 shares of the company’s stock valued at $2,909,000 after buying an additional 271,278 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Transenterix by 22.8% in the first quarter. Geode Capital Management LLC now owns 387,182 shares of the company’s stock valued at $1,645,000 after buying an additional 71,972 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Transenterix during the first quarter valued at approximately $133,000. Finally, National Planning Corp bought a new position in shares of Transenterix during the first quarter valued at approximately $365,000.
TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.
Receive News & Stock Ratings for Transenterix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix Inc and related stocks with our FREE daily email newsletter.